MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to commence no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibUDilast).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -0.70% | -7.19% | -5.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.33% | 69.65M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.50% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MNOV Stock
- News MediciNova, Inc.
- MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166